NasdaqGS:AVXLBiotechs
Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer’s Drug Application
Anavex Life Sciences recently reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative trend vote on the company’s Marketing Authorisation Application for blarcamesine, an investigational oral treatment for early Alzheimer’s disease.
This outcome prompts Anavex to seek a re-examination and submit additional biomarker data, while maintaining regulatory dialogue with both European and U.S. health authorities.
We'll explore how this...